Furthermore, similar to MALAT1, TUG1 expression levels in PBCs decrease after the first-line chemotherapy (Wilcoxon matched-pairs signed rank test, p = 0.003), most likely due to the impact of the therapy on cancer burden, leukocytes (and neutrophils specifically), platelets and endothelial cells, overall leading to a lower TUG1 expression. The gene discussed is MALAT1; the disease is cancer.